NASDAQ · INCR
Healthcare · Drug Manufacturers - Specialty & Generic
$0.99
Up+$0.06 (+6.89%)
Updated Aug 16, 2026, 1:01 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INCR closed at $0.99 after 20 trading sessions, up 8.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.9262 | $0.99 | $0.9262 | $0.99 | 6.19K |
| Aug 13, 2026 | $0.97 | $0.97 | $0.9261 | $0.9262 | 1.67K |
| Aug 12, 2026 | $0.96 | $0.9999 | $0.92 | $0.9648 | 9.19K |
| Aug 11, 2026 | $0.9383 | $0.96 | $0.9383 | $0.96 | 1.22K |
| Aug 10, 2026 | $0.9506 | $0.99 | $0.9466 | $0.96 | 3.23K |
| Aug 7, 2026 | $0.97 | $0.98 | $0.95 | $0.98 | 80.39K |
| Aug 6, 2026 | $0.9621 | $0.9621 | $0.9253 | $0.9253 | 1.86K |
| Aug 5, 2026 | $0.94 | $0.9527 | $0.9378 | $0.9517 | 3.51K |
| Aug 4, 2026 | $0.9671 | $0.9671 | $0.92 | $0.9629 | 5.4K |
| Aug 3, 2026 | $0.96 | $0.9999 | $0.9232 | $0.9529 | 8.43K |
| Jul 31, 2026 | $0.99 | $0.99 | $0.945 | $0.9618 | 17.11K |
| Jul 30, 2026 | $0.915 | $0.99 | $0.9127 | $0.9484 | 13.89K |
| Jul 29, 2026 | $0.9255 | $0.9255 | $0.876 | $0.8763 | 24.06K |
| Jul 28, 2026 | $0.9275 | $0.94 | $0.898 | $0.9195 | 18.93K |
| Jul 27, 2026 | $0.90 | $0.9788 | $0.90 | $0.903 | 14.51K |
| Jul 24, 2026 | $0.89 | $0.966 | $0.89 | $0.966 | 13.23K |
| Jul 23, 2026 | $0.9999 | $0.9999 | $0.93 | $0.953 | 24.99K |
| Jul 22, 2026 | $0.9109 | $0.9598 | $0.9109 | $0.94 | 12.06K |
| Jul 21, 2026 | $0.8712 | $0.9151 | $0.8711 | $0.9072 | 16.42K |
| Jul 20, 2026 | $0.9056 | $0.9395 | $0.88 | $0.91 | 14.43K |
The latest Smart Investors Daily articles mentioning INCR.
INCR research
Company profile and research snapshot.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jun 22, 2026
InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opportunities
Benzinga · Jun 15, 2026
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and
Benzinga · Mar 3, 2026
InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the
Benzinga · Feb 19, 2026
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA.Revenue for 2025 represents an increase of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INCR.
No results
No recent SID articles mention INCR.
